Study in Children and Adolescents of 177Lu-DOTATATE (Lutathera®) Combined With the PARP Inhibitor Olaparib for the Treatment of Recurrent or Relapsed Solid Tumours Expressing Somatostatin Receptor (SSTR) (LuPARPed).

Trial Details

NCT ID

NCT06607692

Phase

PHASE1 / PHASE2

Sponsor

Fundación de investigación HM

Status

RECRUITING

Cancer Type

Osteosarcoma Sarcoma

Interventions

• Olaparib; 177Lu-DOTATATE

Locations (sample)

• Boadilla del Monte, Madrid, Spain|40.405,-3.87835

Key Eligibility Criteria

• 18 months - 18 years of age at the time of the initial diagnosis.
• ≥ 3 years at the moment of inclusion in the trial.
• Diagnosis: relapsed/refractory solid tumours with positive uptake on SSTR-PET (PET-CT or PET-MRI), performed in the previous three months before en…
• The evaluation of SSTR expression will be classified according to a qualitative 4-point scale: SSTR expression V (visual score):

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.